Free Float 77,58 %
Shares Float 135,51 M
Shares Outstanding 174,66 M
INTELGENX TECHNOLOGIES Share · US45822R1014 · A0RP0X (XTSX) Principal · Canada · Healthcare — real-time prices and quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of INTELGENX TECHNOLOGIES
No Price
Share Float & Liquidity
Asset Allocation
| Asset | Percentage % |
|---|---|
| Equity | 2,27 % |
Largest Positions
Updated on May 18 2026, 5:04 PM
| Symbol | ISIN | CUSIP | Name | Shares | Market Value | Percentage % |
|---|---|---|---|---|---|---|
| GVMXX | US8574927062 | 857492706 | STATE STREET INSTITUTIONAL US STATE ST INST US GOV MM PREM | 4,06 M IDX | 4,06 M EUR | 2,27 % |
Country Distribution
| Country | Percentage % |
|---|---|
| USA | 2,27 % |
Sector Distribution
| Sector | Percentage % |
|---|---|
| Financial Services | 2,27 % |
Industry Distribution
| Industry | Percentage % |
|---|---|
| Asset Management | 2,27 % |
Currency Distribution
| Currency | Percentage % |
|---|---|
| USD | 2,27 % |
Company Profile for INTELGENX TECHNOLOGIES Share
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Fund Master Data
Issuer Principal
Asset Class ETF
Name Principal Exchange-Traded Funds - Principal Investment Grade Corporate Active ETF
Fund Currency USD
Fund Key Figures
Fund Size 486.880,38 USD
Investment Strategy
The investment seeks to provide current income and, as a secondary objective, capital appreciation. The fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets, plus any borrowings for investment purposes, in investment grade corporate bonds and other fixed income securities at the time of purchase. Investment grade securities are rated BBB- or higher by S&P Global Ratings (S&P Global) or Baa3 or higher by Moody's Investors Service, Inc. (Moody's) or, if unrated, of comparable quality in the opinion of those selecting such investments.
Updated on Aug 22 2021, 12:00 AM
Company Data
Name INTELGENX TECHNOLOGIES
Company IntelGenx Technologies Corp.
Website
https://www.intelgenx.com
Primary Exchange 
TSX-V
TSX-V
WKN A0RP0X
ISIN US45822R1014
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dwight Gorham
Market Capitalization 42 Mio
Country Canada
Currency EUR
Employees -
Address 6420 Abrams, H4S 1Y2 Montreal
IPO Date 2008-05-27
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | IGXT |
| TSX | IGX.TO |